Nucleoside-Lipid-Based Nanocarriers for Sorafenib Delivery

Nucleoside-Lipid-Based Nanocarriers for Sorafenib Delivery

Abstract Although the application of sorafenib, a small inhibitor of tyrosine protein kinases, to cancer treatments remains a worldwide option in chemotherapy, novel strategies are needed to address the low water solubility (< 5 μM), toxicity, and side effects issues of this drug. In this context...

Full description

Bibliographic Details
Main Authors: Sebastien Benizri, Ludivine Ferey, Bruno Alies, Naila Mebarek, Gaelle Vacher, Ananda Appavoo, Cathy Staedel, Karen Gaudin, Philippe Barthélémy
Format: Article
Language:English
Published: SpringerOpen 2018-01-01
Series:Nanoscale Research Letters
Subjects:
Sorafenib
Solid lipid nanoparticles
Nucleolipids
Hepatocarcinoma
Breast carcinoma
Luminal B
Online Access:http://link.springer.com/article/10.1186/s11671-017-2420-2

Internet

http://link.springer.com/article/10.1186/s11671-017-2420-2

Similar Items